DGX
ACCE-researchedOverview
ACCE thesis
Quest Diagnostics operates the largest clinical lab network in America, processing 150 million tests annually across 2,200 patient service centers and partnerships with 7,000 hospitals. The company's scale advantage creates a defensive moat through route density economics and direct payer relationships that smaller labs can't replicate. Management expects 4-6% organic revenue growth driven by an aging population requiring 3-4% more lab tests per year, plus continued market share gains from hospital outsourcing trends. Trading at 16.9x forward earnings with 14.5% ROE, DGX offers steady cash generation in a recession-resistant business that thrived during COVID disruptions. The stock yields 1.8% with consistent buybacks reducing share count by 2-3% annually.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
Valuation
INVESTORSix independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORThe full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROFollow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| MTD | Mettler-Toledo International Inc. Common Stock | $27.9B | 31.3 | 29.5% | -91.05 | 0.0% | - | Compare |
| LH | Labcorp Holdings Inc. Common Stock | $26.0B | 26.5 | 11.7% | 0.65 | 0.9% | - | Compare |
| GH | Guardant Health Inc. Common Stock | $24.1B | - | -4584.5% | -15.42 | 0.0% | - | Compare |
| ILMN | Illumina Inc. Common Stock | $36.2B | 44.6 | 32.3% | 0.73 | 0.0% | - | Compare |
| IDXX | IDEXX Laboratories Inc. Common Stock | $40.3B | 36.0 | 74.2% | 0.53 | 0.0% | - | Compare |
| WAT | Waters Corporation Common Stock | $41.4B | 106.5 | 1.9% | 0.73 | 0.0% | - | Compare |
Sector report card
Where DGX ranks against its sector peers on each metric.
News and Record
Press releases mentioning this company
- PR Newswire•Sep 16, 2026Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
- PR Newswire•Sep 9, 2026Apple Health app Users to be Able to Order Labs from Quest Diagnostics
- GlobeNewswire•Sep 4, 2026Clinical Laboratory Services Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.